Acurx Pharmaceuticals (ACXP)
(Delayed Data from NSDQ)
$2.01 USD
-0.01 (-0.50%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $2.01 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Acurx Pharmaceuticals, Inc. [ACXP]
Reports for Purchase
Showing records 1 - 16 ( 16 total )
Company: Acurx Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Recap: CMC Meeting With FDA to Enable Ibezapolstat''s Phase 3 Initiation; Partnership Talks Continue; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Acurx Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q Recap: Details of Ibezapolstat Phase 3 CDI Program Hashed Out in End of Phase 2 Meeting With FDA
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Acurx Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap; EOP2 Meeting to Enable First Phase 3''s Start in 4Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Acurx Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Good News Comes in Pairs; FDA EOP2 Meeting Scheduled For Late April; EMA Granted SME Designation; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Acurx Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
New Comparative Microbiology and Microbiome Analysis Highlights Additional Advantages With Ibezapolst; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Acurx Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Further Evidence of Ibezapolstat Treatment Benefit: 100% Sustained Clinical Cure One Month Later; Increasing PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Acurx Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap; With Positive Phase 2 Data in Hand, Acurx Prepares For EOP2 Meeting With FDA Near End of 1Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Acurx Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Ibezapolstat Reached 96% Clinical Cure Rate in Phase 2; Phase 3 Discussions With FDA Near End of 1Q24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Acurx Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Data Support Phase 2b Ibezapolstat CDI Study''s Early Termination
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Acurx Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2b Ibezapolstat CDI Study to Reach Interim Analysis in Coming Months; Cash Runway Through 3Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Acurx Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap: Interim Analysis on Phase 2b Ibezapolstat Study Soon; Cash Runway to 3Q24; Affirm Buy, Adjust PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Acurx Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q Recap; Phase 2b CDI Study Interim Analysis Now Expected in 2H23; CARB-X Could Provide $11.3M in Funding; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Acurx Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Accepts Protocol Amendment to Include Interim Analysis Plan; We Expect Interim Data in Mid-2023; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Acurx Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q Recap: Phase 2b CDI Study Interim Analysis On Target in Mid-2023; Ibezapolstat Could Advance Into Phase 3; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Acurx Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Approaching Ibezapolstat Phase 2b CDI Study Enrollment Update in March; Data Readout Expected in Mid-2023; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Acurx Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Ibezapolstat May Become the Standard of Care for C. Diff Infection; Phase 2b Data Likely in 1H23; Initiate Buy, $14 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
|